Pexidartinib
| Catalog Number | Pack Size | List Price* | Quantity | |
|---|---|---|---|---|
| HY-16749-5MG | 5 mg | 77,00 | Add | |
| HY-16749-1ML | 10mM/1mL | 83,00 | Add | |
| HY-16749-10MG | 10 mg | 102,00 | Add | |
| HY-16749-50MG | 50 mg | 204,00 | Add | |
| HY-16749-100MG | 100 mg | 254,00 | Add | |
| HY-16749-200MG | 200 mg | 343,00 | Add | |
| HY-16749-500MG | 500 mg | 584,00 | Add | |
| HY-16749-1G | 1 g | 964,00 | Add | |
| HY-16749-2G | 2 g | 1'597,00 | Add | |
| HY-16749-5G | 5 g | 3'370,00 | Add | |
| HY-16749-10G | 10 g | 4'891,00 | Add | |
| HY-16749-20G | 20 g | 8'691,00 | Add | |
| HY-16749-S-1ST | Sample | Inquire |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Best price guarantee – we offer you the lowest price in Switzerland. Please contact us for a quote if needed.
Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity[1].
| Category | Biochemicals |
| Supplier | MedChem Express |
| Regulatory Status | RUO |
| Research Field | Cancer, Apoptosis,Protein Tyrosine Kinase/RTK |
| Format | Solubility: DMSO : 100 mg/mL (ultrasonic) |
| Grade | Clinical information: Launched |
| Purity | 99.64% |
| Molecular Formula | C20H15ClF3N5 |
| Molecular Weight | 417.81 |
| CAS-Number | 1029044-16-3 |
| Storage Conditions | -20°C, 3 years; 4°C, 2 years (Powder) |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.medchemexpress.com |
| Shipping Details | Room Temperature |
| Material Safety Data Sheet | Download PDF |
